All
Early Immunotherapy Data: 8 Questions With a Bladder Cancer Expert
July 19th 2016The FDA granted the PD-L1 inhibitor Tecentriq an accelerated approval in May 2016 as a treatment for patients with locally advanced or metastatic urothelial carcinoma, following encouraging results of the phase 2 IMvigor 210 study.
If "Cancer" Is in the Fine Print, Run the Other Way
July 18th 2016There are so many choices on the market to confuse us about healthy living. Let us be thankful that many products come with warning labels to alert us to potential cancer risks, even if they are sometimes so small we overlook them at first glance.